Right- and left-sided colorectal cancers respond differently to cetuximab

摘要: Right-sided colon cancer (RSCC) and left-sided colorectal (LSCRC) differ with respect to their biology genomic patterns. This study aimed examine whether the primary tumor location is associated response cetuximab in patients metastatic (mCRC). Patients mCRC treated standard chemotherapy as first- or second-line treatments were compared randomly chosen who alone between 2005 2013. The main outcome measures overall rate (ORR), progression-free survival (PFS), (OS). differences analyzed by using chi-squared test, Student’s t Kaplan-Meier method. treatment results of 206 those 210 alone. As a first-line treatment, was significantly higher ORR (49.4 % vs. 28.6 %, P = 0.005) well longer PFS (9.1 6.2 months, P = 0.002) OS (28.9 20.1 months, P = 0.036) than LSCRC. However, neither improved (36.4 26.2 P = 0.349) nor prolonged (5.6 5.7 months, P = 0.904) (25.1 19.8 months, P = 0.553) RSCC. exhibited tendency improve (23.5 10.2 P = 0.087) prolong (4.9 3.5 months, P = 0.064), it (17.1 12.4 months, P = 0.047) In contrast, (7.1 11.4 P = 0.698) (3.3 4.2 months, P = 0.761) (13.4 13.0 months, P = 0.652) addition both may only benefit